4th Quarter - Report
EISAI INC. for EISAI INC.
Firm
Client
Income
—
Expenses
$380,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Drug issues; FDA-DEA issues Prescription Drug User Fee Act Authorization "Track and Trace" legislation
| Lobbyist | Covered position, as disclosed |
|---|---|
| PETER NORMAN | — |
| KATIE OPPENHEIM | Legislative Assistant, Senator Mike Crapo |
Financial Institutions/Investments/Securities FIN
Student Loan Auction Rate Securities
| Lobbyist | Covered position, as disclosed |
|---|---|
| PETER NORMAN | — |
| KATIE OPPENHEIM | Legislative Assistant, Senator Mike Crapo |
Health Issues HCR
Obesity awareness as a medical condition Metastic breast cancer awareness
| Lobbyist | Covered position, as disclosed |
|---|---|
| PETER NORMAN | — |
| KATIE OPPENHEIM | Legislative Assistant, Senator Mike Crapo |
Education EDU
Student Loan Auction Rate Securities
| Lobbyist | Covered position, as disclosed |
|---|---|
| PETER NORMAN | — |
| KATIE OPPENHEIM | Legislative Assistant, Senator Mike Crapo |
Medicare/Medicaid MMM
Coverage and reimbursement issues Average Sales Price reduction for Part B products Repeal Medicare Part D coverage exclusion for obesity drugs H.R. 6684, Spending Reduction Act of 2012 H.R. 8, American Taxpayer Relief Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| PETER NORMAN | — |
| KATIE OPPENHEIM | Legislative Assistant, Senator Mike Crapo |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.